We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights.
- Authors
Nachmias, Boaz; Aumann, Shlomzion; Haran, Arnon; Schimmer, Aaron D.
- Abstract
Summary: Venetoclax, an oral BCL‐2 inhibitor, has been widely incorporated in the treatment of acute myeloid leukaemia. The combination of hypomethylating agents and venetoclax is the current standard of care for elderly and patient's ineligible for aggressive therapies. However, venetoclax is being increasingly used with aggressive chemotherapy regimens both in the front line and in the relapse setting. Our growing experience and intensive research demonstrate that certain genetic abnormalities are associated with venetoclax sensitivity, while others with resistance, and that resistance can emerge during treatment leading to disease relapse. In the current review, we provide a summary of the known mechanisms of venetoclax cytotoxicity, both regarding the inhibition of BCL‐2‐mediated apoptosis and its effect on cell metabolism. We describe how these pathways are linked to venetoclax resistance and are associated with specific mutations. Finally, we provide the rationale for novel drug combinations in current and future clinical trials.
- Subjects
ACUTE myeloid leukemia; VENETOCLAX; AZACITIDINE; APOPTOSIS inhibition; OLDER patients; CELL metabolism
- Publication
British Journal of Haematology, 2024, Vol 204, Issue 4, p1146
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19314